Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SPARC Antibodies:
anti-Mouse (Murine) SPARC Antibodies:
anti-Rat (Rattus) SPARC Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal SPARC Primary Antibody for CyTOF, FACS - ABIN4899335
Arnold, Rivera, Carbon, Toombs, Chang, Bradshaw, Brekken: Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF? activation. in PLoS ONE 2012
Show all 11 Pubmed References
Human Polyclonal SPARC Primary Antibody for CyTOF, FACS - ABIN4899340
Aguilera, Rivera, Hur, Carbon, Toombs, Goldstein, Dellinger, Castrillon, Brekken: Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. in Cancer research 2014
Show all 7 Pubmed References
Mouse (Murine) Monoclonal SPARC Primary Antibody for CyTOF, FACS - ABIN4899334
Weaver, Sage, Yan: Absence of SPARC in lens epithelial cells results in altered adhesion and extracellular matrix production in vitro. in Journal of cellular biochemistry 2006
Show all 5 Pubmed References
Human Polyclonal SPARC Primary Antibody for IF (p), IHC (p) - ABIN738141
Chen, Wang, Xi, Xue, He, Zhang, Zhao: SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. in PLoS ONE 2012
Show all 3 Pubmed References
Human Polyclonal SPARC Primary Antibody for FACS, WB - ABIN4899336
Xu, Ping, Yin, Xiao, Xiang, Ballantyne, Wu, Li: Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. in PLoS ONE 2013
Show all 2 Pubmed References
Human Polyclonal SPARC Primary Antibody for IHC, IHC (fro) - ABIN4355498
Kato, Nicholson, Neiman, Rantalainen, Holmes, Barrett, Uhlén, Nilsson, Spector, Schwenk: Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model. in Proteome science 2011
Show all 2 Pubmed References
Human Monoclonal SPARC Primary Antibody for CyTOF, FACS - ABIN4899338
Moreno, Ball, Andrade, McDermid, Stanimirovic: Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. in Glia 2006
Show all 2 Pubmed References
Human Monoclonal SPARC Primary Antibody for CyTOF, FACS - ABIN4899339
Grønborg, Kristiansen, Iwahori, Chang, Reddy, Sato, Molina, Jensen, Hruban, Goggins, Maitra, Pandey: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. in Molecular & cellular proteomics : MCP 2006
Show all 2 Pubmed References
Human Polyclonal SPARC Primary Antibody for ELISA, IHC - ABIN1585713
Wehrle-Martinez, Dittmer, Aberdein, Thompson: Osteocalcin and Osteonectin Expression in Canine Osteosarcoma. in Veterinary pathology 2017
Human Monoclonal SPARC Primary Antibody for ELISA, WB - ABIN562974
Piconese, Costanza, Tripodo, Sangaletti, Musio, Pittoni, Poliani, Burocchi, Passafaro, Gorzanelli, Vitali, Chiodoni, Barnaba, Pedotti, Colombo: The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. in Journal of autoimmunity 2011
The profiled circulating tumour cells also expressed elevated levels of stem cell markers, and the extracellular matrix protein, SPARC. The expression of SPARC might correspond to an epithelial-mesenchymal transition in pancreatic circulating tumour cells
Data suggest that both osteonectin and FGF21 (show FGF21 Antibodies) levels in serum are associated with early nephropathy in type 2 diabetes, albeit with different patterns; persistent hyperglycemia may inhibit bone formation leading to osteoporosis. (FGF21 (show FGF21 Antibodies) = fibroblast growth factor 21 (show FGF21 Antibodies))
These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer.
High expression of SPARC is related to worse prognosis in rectal cancer patients.
Tumors with stroma-derived SPARC displayed suppressed growth, inhibited angiogenesis and increased lipid accumulation. Based on the described chaperone function of SPARC, authors hypothesized that SPARC binds albumin (show ALB Antibodies) complexed with fatty acids and transports them to tumors.
Weekly NAB-paclitaxel might be effective for heavily pretreated non-small-cell lung cancer patients. SPARC expression in tumor stroma cells might be a potential negative predictor of NAB-paclitaxel.
SPARC-associated signaling pathways are associated with lymphangiogenesis and lymph node metastases of hypopharyngeal cancer.
Stromal SPARC expression correlated with the prognosis of patients with resectable biliary carcinoma, and its significance was enhanced in patients treated with adjuvant gemcitabine-based chemotherapy.
Studies revealed that SPARC plays a critical role in regulating bone remodeling and maintaining bone mass and quality. The mechanisms by which SPARC influences bone formation, maintenance, and repair might occur through multiple pathways that include the regulation of procollagen processing and assembly in the bone matrix, crosslinking, mineralization, and/or osteoblast/osteoclast differentiation and activity. [review]
This study indicates that germline PTCH1 (show PTCH1 Antibodies) heterozygous mutations play a major role in bone metabolism in patients with NBCCS (show PTCH1 Antibodies), in particular in those with PTCH1 (show PTCH1 Antibodies) protein truncation mutations. SPARC may represent an important downstream modulator of PTCH1 (show PTCH1 Antibodies) mediation of bone metabolism.
SPARC is regulating the interplay between myeloid-derived suppressor cells and the extracellular matrix to drive the induction of epithelial-to-mesenchymal transition in tumor cells.
The results demonstrate for the first time a functional role of the N-propeptide in regulating collagen fiber assembly and cell behavior and suggest that SPARC and the N-propeptide of collagen I have distinct activities in regulating collagen fiber assembly and fibroblast function.
SPARC plays a key role in influencing the spatial organization of the anterior segment, potentially via modulation of collagen properties, while Hevin is not likely to be involved.
An ADAMTS1 (show ADAMTS1 Antibodies) blocking antibody suppressed the SPARC-induced collagen I secretion, indicating that SPARC promoted collagen production directly through ADAMTS1 (show ADAMTS1 Antibodies) interaction. In conclusion, ADAMTS1 (show ADAMTS1 Antibodies) is an important mediator of SPARC-regulated cardiac aging.
SPARC appears to be an important modulator of the actin cytoskeleton, implicating maintenance of muscular function
resistivity measurements were taken on 22 mice, 11 wild-type and 11 sparc-/- (knock out for the protein SPARC: secreted protein acidic and rich in cysteine), bearing mammary carcinomas.
SPARC isoforms, acting on Adipose stromal cells through distinct mechanisms, have an additive effect in inducing ASC (show STS Antibodies) migration.
SPARC levels were not associated with efficacy in patients with MPC. This exploratory analysis does not support making treatment decisions regarding nab-paclitaxel plus gemcitabine or gemcitabine alone in MPC based on SPARC expression.
SPARC is proposed to act as a critical regulator of transglutaminase activity on collagen I with implications for mechanical strength of tissues.
Tumor-produced SPARC and VCAM1 (show VCAM1 Antibodies) are regulators of cancer extravasation.
findings indicate that secreted protein acidic cysteine-rich (SPARC) is intricately regulated by pro-angiogenic and other growth factors together with components of the extracellular matrix during the follicle-luteal transition
This study reports the temporal changes in vascular endothelial growth factor A (VEGFA (show VEGFA Antibodies)), fibroblast growth factor 2 (FGF2 (show FGF2 Antibodies)) and osteonectin during the follicular-luteal transition and corpus luteum development in the cow.
these data identify a contributory role for DNA methylation (show HELLS Antibodies) in regulating sparc expression in zebrafish embryogenesis.
Results establish a role for an ECM (show MMRN1 Antibodies) protein (Sparc) as an important regulator of embryonic haematopoiesis during early development in zebrafish.
Data show that Sparc (Osteonectin) functions in morphogenesis of the pharyngeal skeleton and inner ear in zebrafish.
Sparc is directly required for normal otolith growth
data suggest that SPARC might modulate angiogenesis during wound healing in the horse, which could protect against the disproportionate fibroplasia commonly afflicting limb wounds and leading to the development of exuberant granulation tissue
Data suggest a critical requirement for SPARC during post-gastrula development in Xenopus embryos and that SPARC, directly or indirectly, promotes cell-cell adhesion in vivo.
This gene encodes a cysteine-rich acidic matrix-associated protein. The encoded protein is required for the collagen in bone to become calcified but is also involved in extracellular matrix synthesis and promotion of changes to cell shape. The gene product has been associated with tumor suppression but has also been correlated with metastasis based on changes to cell shape which can promote tumor cell invasion.
, basement-membrane protein 40
, cysteine-rich protein
, secreted protein acidic and rich in cysteine
, Secreted acidic cystein-rich glycoprotein (osteonectin)
, secreted acidic cysteine rich glycoprotein
, secreted protein, acidic, cysteine-rich (osteonectin) S homeolog
, secreted protein, acidic, cysteine-rich (osteonectin)